Dotmatics Limited, a leading provider of scientific informatics solutions and services to the pharmaceutical and biotechnology industries, announces that one of the world’s most influential cancer research institutes, The Institute of Cancer Research, London, has deployed its premium data visualisation and analysis tool Vortex, to help in the quest to discover and develop new cancer drugs.
Dotmatics’ Vortex is a world-class visualisation and analytics platform designed specifically for analysis and interrogation of scientific data. Vortex provides users with an out-of the-box filtering, charting, plotting and chemically aware calculations engine, enabling scientists to evaluate large datasets in a rich, intuitive and flexible user interface. The use of Vortex helps uncover hidden data trends and correlations and identify new potential drug candidates.
After rigorous internal testing, The Institute of Cancer Research (ICR) selected Dotmatics’ Vortex because of its “flexibility, ease of use and swift integration with our existing chemoinformatics data storage platform,” said Professor Julian Blagg, Head of Chemistry and Deputy Director of the Division of Cancer Therapeutics at The Institute of Cancer Research. “It allows the visualisation of multidimensional datasets on compounds of interest to study trends, relationships and to discover outliers,” he added.
“We are delighted that such a prestigious cancer research organisation has chosen Dotmatics as their informatics supplier,” said Dr. Stephen Gallagher, CEO of Dotmatics. “We invest heavily in Vortex to guarantee that it continues to be the best data analysis and visualisation tool for scientists across the world. We will continue to work with the ICR to ensure the development of our solutions matches their ever changing needs” he added.